Pfizer jumps on positive Covid-19 vaccine trial data
By Alexander Bueso
Date: Wednesday 01 Jul 2020
(Sharecast News) - Shares of drug giant Pfizer were boosted by news of positive clinical trial results for a Covid-19 vaccine candidate known as BNT162b1.
Meanwhile, stock in BioNTech, the other company involved in its development, were halted.
All 24 volunteers enrolled in their Phase 1/2 trial who were dosed with one of two lower doses of the vaccine generated neutralising antibodies.
The results of the clinical study, which involved a total of 45 patients, had yet to be peer-reviewed.
Reports indicated that the level of antibodies created was the same or greater than those present in convalescent sera from people who had suffered and recovered from the illness.
No serious adverse events were reported in the study.
The Phase 1/2 trial was ongoing for another three vaccine candidates, the results of which, together with Wednesday's announcement, would decide which would be employed in a 2b/3 trial with 30,000 patients that may start as soon as July.
As of 1509 BST, shares of Pfizer were 3.88% higher at $33.97.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN